Key takeaways:
- Latozinemab is an investigational human monoclonal antibody.
- The drug is currently being examined in a phase 3 clinical trial.
The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.
According to a press release from Alector Inc., the breakthrough designation was approved based on data from the phase 2 INFRONT-2 clinical trial of latozinemab in patients with the condition.
CNMRI: Neurology, Sleep Medicine, MRI 